{
    "nctId": "NCT02209389",
    "briefTitle": "OctavaPink for Women With Dense Breast After Negative Mammography",
    "officialTitle": "OctavaPink\u00ae For Dense Breast After Negative Mammography",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1750,
    "primaryOutcomeMeasure": "Positive MRI as an approval for a positive OctavaPink test",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects with dense breast tissue according to ACR criteria, (BIRADS composition/density 3 or 4), or with specific area of high density behind the nipple.\n* Subject with current mammography BIRADS assessment category other than 3.\n* Signed inform consent form.\n\nAdditional inclusion criteria for Part 1A and Part 1B cases and Part 3 cases\n\n\u2022 Subjects with current biopsy/surgery proven breast cancer.\n\nAdditional inclusion criteria for Part 1A controls, Part 1B controls \u2022 Subjects with current negative mammography (BIRADS assessment category 1 or 2).\n\nAdditional inclusion criteria for Part 2\n\n\u2022 Subjects with current negative mammography (BIRADS assessment category 1 or 2). All will perform an additional 1 year (12-18 months) up mammography to verify negative results.\n\nAdditional inclusion criteria for Part 3 \u2022 Enriched patient population - Subjects with current/recent (less than 12 months) negative mammography (BIRADS assessment category 1 or 2). Mammography evaluation can be performed after recruiting.\n\nExclusion Criteria:\n\n* Previous or concurrent malignancies of any type except for basal cell carcinoma of the skin, squamous-cell carcinoma of the skin or cervical carcinoma in situ.\n* Previous or current ADH, ALH, LCIS.\n* Autoimmune disorders diagnosed subjects.\n* Hematological malignancies.\n* Subjects under active chemotherapy treatment or chemotherapy in the past 6 months.\n* Steroid treatment in the past 3 months.\n* Subject undergoing immunosuppressive treatments.\n* Subject with current mammography BIRADS assessment category of 3.\n* Pregnancy at time of recruitment.\n* Doctor medical judgment that prohibits participation in the study.\n* Participating in a parallel clinical study that involves drug treatment, or may influence the course of this clinical trial.\n\nAdditional exclusion criteria for Part 3\n\n\u2022 Subjects with current mammography BIRADS assessment other than 1 or 2.",
    "sex": "FEMALE",
    "minimumAge": "30 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}